Melatonin supplementation To reduce the Induction of labour rate in first-time MothErs: The My TIME Clinical Trial


Are you interested in the MyTIME clinical trial?


MyTIME is a double-blinded, randomised, placebo-controlled clinical trial funded by the Medical Research Future Fund, and led by Dr Zoe Bradfield from Curtin University, Western Australia.  The MyTIME trial will evaluate if daily melatonin supplementation from week 39 of pregnancy will reduce induction of labour rates, as melatonin works with oxytocin to support uterin contractions.  We will also explore how melatonin affects sleep quality and duration, and blood glucose levels of those with gestational diabetes in pregnancy.

Around 530 women from the Women and Newborn Health Service will take part in this study.  They will be from King Edward Memorial Hospital, Osborne Park Hospital, The Family Birth Centre and the Community Midwifery Program.

The Study medication is melatonin 3mg, which is taken orally.  Melatonin is known to be safe for pregnant women and babies.  We hope the results from this study will provide women with greater opportunity to avoid unnecessary induction of labour in the future.

             If you are interested in participating or would like further information, please contact Principal Investigator Dr Zoe Bradfield and the rest of the MyTIME team at
                                                                                                            for more information

This study has been approved by the Women and Newborn Health Services HREC (RGS0000006283).
The MyTIME trial is sponsored by the Medical Research Future Fund (GNTMRFF#2023945) and Curtin University.
ANZ Clinical Trial Registry number: ACTRN12623000502639p.

Copyright © CCRE. All Rights Reserved
Centre for Clinical Research and Education
Address: School of Population Health, Curtin University, Bentley WA 6102